Cocrystal Pharma, Inc. (COCP)
US — Healthcare Sector
Automate Your Wheel Strategy on COCP
With Tiblio's Option Bot, you can configure your own wheel strategy including COCP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COCP
- Rev/Share 0.0
- Book/Share 0.9077
- PB 2.2705
- Debt/Equity 0.2373
- CurrentRatio 4.5707
- ROIC -1.7772
- MktCap 16583294.0
- FreeCF/Share -1.4666
- PFCF -1.1114
- PE -1.0464
- Debt/Assets 0.1626
- DivYield 0
- ROE -1.3512
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
COCP
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla.
Read More
About Cocrystal Pharma, Inc. (COCP)
- IPO Date 2012-02-22
- Website https://www.cocrystalpharma.com
- Industry Biotechnology
- CEO Dr. Sam Lee Ph.D.
- Employees 11
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.